Company intelligence / Profile preview

Libra Partnership

San Diego, CA, USAthelibrapartnership.com ↗

Ownership: Private
Development stage: Other

Overview

Libra Therapeutics develops novel small molecules to restore lysosomal function and autophagy, aiming to halt or slow progression of neurodegenerative diseases. Their lead TRPML1 activator program will enter Phase 1 trials in 2025. Two additional preclinical programs are at the target validation stage. No clinical results yet reported.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Partnerships

Axxam S.p.A. — provides proprietary chemical matter, exclusive assays, drug discovery expertise.Multiple international CROs handle R&D operations as part of a virtual biotech model.

Beyond the preview

Go deeper on Libra Partnership.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Libra Partnership.

Explore the full profile